Psoralidin / P53 Cancer Research Results

PSO, Psoralidin: Click to Expand ⟱
Features:
Psoralidin is a prenylated coumestan isolated primarily from Psoralea corylifolia (Babchi). It is not a classical anticancer drug.
Psoralidin generally acts to suppress oncogenic signaling and survival pathways while promoting apoptosis in tumor cells.
Reported effects (context-dependent, preclinical):
-DOWNREGULATES pro-survival pathways (e.g., NF-κB, STAT3)
-UPREGULATES apoptotic signaling (caspase activation)
-MODULATES androgen receptor signaling in prostate cancer models
-SENSITIZES tumor cells to chemo- and radio-induced stress

This positions psoralidin as a biologic modulator, not a driver.

Across cancer cell and animal models, psoralidin has been associated with:
-Apoptosis induction
  -Caspase activation
  -Mitochondrial depolarization
-Inflammatory pathway suppression
  -NF-κB inhibition
  -STAT3 attenuation
-Hormone signaling modulation
  -Androgen receptor suppression (prostate cancer context)
-Oxidative stress interaction
  -Redox imbalance tipping tumor cells toward death under stress

Psoralidin is best described as chemopreventive or chemo-sensitizing, not chemoprotective


P53, P53-Guardian of the Genome: Click to Expand ⟱
Source: TCGA
Type: Proapototic
TP53 is the most commonly mutated gene in human cancer. TP53 is a gene that encodes for the p53 tumor suppressor protein ; TP73 (Chr.1p36.33) and TP63 (Chr.3q28) genes that encode transcription factors p73 and p63, respectively, are TP53 homologous structures.
p53 is a crucial tumor suppressor protein that plays a significant role in regulating the cell cycle, maintaining genomic stability, and preventing tumor formation. It is often referred to as the "guardian of the genome" due to its role in protecting cells from DNA damage and stress.
TP53 gene, which encodes the p53 protein, is one of the most frequently mutated genes in human cancers.
Overexpression of MDM2, an inhibitor of p53, can lead to decreased p53 activity even in the presence of wild-type p53.
In some cancers, particularly those with mutant p53, there may be an overexpression of the p53 protein.
Cancers with overexpression: Breast, lung, colorectal, overian, head and neck, Esophageal, bladder, pancreatic, and liver.
Scientific Papers found: Click to Expand⟱
4968- PSO,    Psoralidin: emerging biological activities of therapeutic benefits and its potential utility in cervical cancer
- in-vitro, Cerv, NA
*Inflam↓, *antiOx↑, *neuroP↑, *AntiDiabetic↑, *Bacteria↓, AntiTum↑, CSCs↓, ROS↑, TumAuto↑, Apoptosis↑, ChemoSen↑, RadioS↑, BioAv↓, *cardioP↑, *ROS↓, *LDH↓, TumCP↓, TRAIL⇅, TumCMig↓, EMT↓, NF-kB↓, P53↑, Casp3↑, NOTCH↓, CSCs↓, angioG↓, VEGF↓, Ki-67↓, CD31↓, TRAILR↑, MMP↓, BioAv↓, BioAv↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ROS↑, 1,  

Mitochondria & Bioenergetics ⓘ

MMP↓, 1,  

Cell Death ⓘ

Apoptosis↑, 1,   Casp3↑, 1,   TRAIL⇅, 1,   TRAILR↑, 1,  

Autophagy & Lysosomes ⓘ

TumAuto↑, 1,  

DNA Damage & Repair ⓘ

P53↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

CSCs↓, 2,   EMT↓, 1,   NOTCH↓, 1,  

Migration ⓘ

CD31↓, 1,   Ki-67↓, 1,   TumCMig↓, 1,   TumCP↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   VEGF↓, 1,  

Immune & Inflammatory Signaling ⓘ

NF-kB↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 2,   BioAv↑, 1,   ChemoSen↑, 1,   RadioS↑, 1,  

Clinical Biomarkers ⓘ

Ki-67↓, 1,  

Functional Outcomes ⓘ

AntiTum↑, 1,  
Total Targets: 24

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   ROS↓, 1,  

Core Metabolism/Glycolysis ⓘ

LDH↓, 1,  

Immune & Inflammatory Signaling ⓘ

Inflam↓, 1,  

Clinical Biomarkers ⓘ

LDH↓, 1,  

Functional Outcomes ⓘ

AntiDiabetic↑, 1,   cardioP↑, 1,   neuroP↑, 1,  

Infection & Microbiome ⓘ

Bacteria↓, 1,  
Total Targets: 9

Scientific Paper Hit Count for: P53, P53-Guardian of the Genome
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:389  Target#:236  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page